1-3 of 3
creatine phosphokinase serum increased
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2869.
https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869
Published: 2017
Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1554.
https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554
Published: 2017
Journal Articles

HyperCKemia in CML Patients on Imatinib Mesylate.

Joanne D. Hewitt, BScN, Deborah A. Rusnak, RN, Nanette Cox-Kennett, MN, Loree M. Larratt, MD, Robert Turner, MD
Journal: Blood
Blood (2007) 110 (11): 2965.
https://doi.org/10.1182/blood.V110.11.2965.2965
Published: 2007